Corresponding author: Masoumeh Asle-Rousta, Department of Physiology, Zanjan Branch, Islamic Azad University, Zanjan, Iran. Email: mrousta@iau.ac.ir; mrousta58@gmail.com. Phone: +98 9125606327
Short title: Effects of Linalool and Ascorbic Acid Chitosan Nanoparticles on Amyloid Plaque Deposition
Abstract
Introduction: Alzheimer's disease (AD) is a progressive neurodegenerative disease. The most important indicators of AD are amyloid plaque deposition and tau hyperphosphorylation. The present study aimed to investigate the effect of linalool and ascorbic acid-chitosan nanoparticles on amyloid plaque deposition in the CA3 region of the hippocampus in AD model rats.
Materials and Methods: Forty male Wistar rats were divided into eight groups: Control, AD, phosphate-buffered saline (PBS), AD-Chitosan, AD-Linalool, AD-nano-Linalool, AD-Ascorbic acid, and AD-nano-Ascorbic acid. The AD model was induced by bilateral intracerebroventricular injection of beta-amyloid (5 μg in 2 μl). Linalool (25 mg/kg), nano-linalool (25 mg/kg), ascorbic acid (100 mg/kg), and nano-ascorbic acid (100 mg/kg) were administered by gavage for 30 days. At the end of the treatment period, the hippocampus was stained with thioflavin S and amyloid plaque deposition in the CA3 region was examined.
Results: The percentage of amyloid plaque deposition in the CA3 region of the hippocampus was significantly lower in the AD-Linalool, AD-nano-Linalool, AD-Ascorbic acid, and AD-nano-Ascorbic acid groups than in the AD group (p < 0.001). Plaque deposition was significantly lower in the AD-nano-Linalool group than in the AD-Linalool group (p < 0.05), and in the AD-nano-Ascorbic acid group than in the AD-Ascorbic acid group (p < 0.01).
Conclusion: Encapsulation of linalool and ascorbic acid in chitosan nanoparticles increased the ability of these natural compounds to reduce amyloid plaque deposition in the hippocampus of AD model rats. Encapsulation may enhance their neuroprotective effects.
Keywords: Alzheimer's disease, Beta-amyloid, Linalool, Ascorbic acid, Hippocampus, Nanochitosan
Introduction
Amyloid beta (Aβ), the main component of amyloid plaques in the brains of patients with Alzheimer's disease (AD), is a promising target for AD treatment [1, 2]. Linalool is an acyclic monoterpene with neuroprotective effects [6, 7] that can reduce Aβ production and tau hyperphosphorylation in AD model mice [8]. Ascorbic acid is a potent antioxidant [9], and its protective effects have been demonstrated in the brains of AD model rats [12].
Research has shown that linalool and ascorbic acid do not completely eliminate nervous system damage in AD; for example, they cannot completely prevent the formation and deposition of amyloid plaques in the brain [8, 12]. Therefore, methods to increase their effectiveness are needed. This study investigated the effect of encapsulating linalool and ascorbic acid in chitosan nanoparticles on amyloid plaque deposition in the CA3 region of the hippocampus in AD model rats.
Methods
Forty adult male Wistar rats were randomly divided into eight groups (five rats per group): (1) Control: intact rats; (2) PBS: animals receiving PBS as the Aβ solvent by intracerebroventricular injection during stereotaxic surgery; (3) AD: rats receiving Aβ1–42 at 10 μg per rat (5 μg per lateral ventricle) by intracerebroventricular injection [16]; (4) AD-Chitosan: rats receiving chitosan (200 mg/kg) after Aβ1–42 injection [17]; (5) AD-Linalool: rats receiving linalool (25 mg/kg) after Aβ1–42 injection [18]; (6) AD-nano-Linalool: rats receiving nano-linalool (25 mg/kg); (7) AD-Ascorbic acid: rats receiving ascorbic acid (100 mg/kg) [12]; and (8) AD-nano-Ascorbic acid: rats receiving nano-ascorbic acid (100 mg/kg).
All rats except those in the Control group underwent stereotaxic surgery. The injection coordinates were AP: −0.8 mm, L: ±1.5 mm, and V: 3.8 mm, selected using a rat brain atlas [20]. Chitosan, linalool, nano-linalool, ascorbic acid, and nano-ascorbic acid were administered by gavage beginning one day after stereotaxic surgery and continuing for 30 consecutive days. At the end of the treatment period, the brain hemispheres were transferred to 10% formalin for histological examination. Sections were taken 2.7–3.7 mm posterior to bregma. Amyloid plaques were stained with 1% thioflavin S, and the percentage of plaque deposition (green staining) was calculated for each animal [21].
Results were expressed as mean ± standard error. One-way analysis of variance followed by Tukey’s post hoc test was used to assess differences among groups. A p value < 0.05 was considered statistically significant.
Results
Field-emission scanning electron microscopy showed that the nanoparticles had an approximately spherical structure, were clustered together, and had diameters below 0.2 μm. Dynamic light scattering confirmed particle diameters of 159 nm for linalool nanoparticles and 125 nm for ascorbic acid nanoparticles.
Amyloid plaque deposition in the CA3 region was significantly higher in the AD group than in the Control group (p < 0.001). Deposition was significantly lower in the AD-Linalool, AD-nano-Linalool, AD-Ascorbic acid, and AD-nano-Ascorbic acid groups than in the AD group (p < 0.001). Plaque deposition was also significantly lower in the AD-nano-Linalool group than in the AD-Linalool group (p < 0.05), and in the AD-nano-Ascorbic acid group than in the AD-Ascorbic acid group (p < 0.001; Figure 4).
Conclusion
Overall, encapsulation of linalool and ascorbic acid in chitosan nanoparticles increased the ability of these natural compounds to reduce amyloid plaque deposition in the CA3 region of the hippocampus in AD model rats.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder that mainly occurs in older adults. Its major pathological hallmarks are extracellular deposition of amyloid plaques and intracellular accumulation of neurofibrillary tangles, which consist of hyperphosphorylated tau protein, in several brain regions, including the hippocampus and neocortex. Amyloid beta (Aβ), the main component of amyloid plaques, is produced from amyloid precursor protein through the amyloidogenic pathway following proteolytic cleavage by beta-secretase and gamma-secretase. According to the amyloid cascade hypothesis, Aβ deposition in the brain marks the initiation of AD pathology because Aβ can trigger tau phosphorylation, synaptic loss, and neuronal death, ultimately leading to cognitive impairment. Aβ is therefore considered a promising target for AD treatment [1, 2]. Pharmaceutical companies have developed synthetic compounds, including verubecestat, LY2886721, and AN-1792, to prevent amyloid plaque deposition. Despite some success in reducing AD symptoms, these compounds produced numerous adverse effects and were not approved. Natural compounds have consequently attracted research interest as potentially safer and less expensive therapeutic options. Current approaches involving natural compounds focus on targeting the secretases responsible for Aβ production or directly interfering with Aβ aggregation [3].
Linalool is an acyclic monoterpene found in various plants, including lavender, bergamot, and eucalyptus. After oral administration, linalool is readily absorbed from the intestine and can cross the blood-brain barrier [4, 5]. Studies have demonstrated its neuroprotective effects [6, 7]. This monoterpene can reduce Aβ production and tau hyperphosphorylation in mice with experimental AD [8].
Ascorbic acid is a water-soluble organic compound found abundantly in fruits and vegetables and is a potent antioxidant [9]. Evidence indicates that plasma ascorbic acid levels are lower in patients with AD than in healthy individuals [10]. Ascorbic acid crosses the blood-brain barrier through the sodium-vitamin C transporter [11]. Its protective effects in the brains of AD model rats have been demonstrated [12].
Although linalool and ascorbic acid have neuroprotective effects in experimental AD, studies indicate that these natural compounds do not completely eliminate the damage; for example, they cannot fully prevent amyloid plaque formation and deposition in the brain [8, 12]. Therefore, strategies are needed to improve their efficacy.
Several challenges complicate drug development for neurological diseases, including AD. One is the selective permeability of the blood-brain barrier, which restricts the entry of many substances into the brain. Another is that many central nervous system drugs must be administered at high doses to achieve adequate efficacy, potentially causing adverse effects. Polymeric nanocarriers offer a promising approach to reducing these limitations. They may facilitate drug delivery across the blood-brain barrier and enable controlled release. Chitosan nanoparticles are biodegradable yet stable carriers with advantages that include biocompatibility, sustained drug release, low toxicity, and relatively simple and inexpensive preparation [13, 14].
The present study was designed to investigate the effect of encapsulating linalool and ascorbic acid in chitosan nanoparticles on amyloid plaque deposition in the CA3 region of the hippocampus in AD model rats.
Materials and Methods
Preparation and characterization of nanoparticles
First, 2 g of linalool (Sigma-Aldrich, USA) and 5 g of ascorbic acid (Sigma-Aldrich, USA) were separately dissolved in 10% dimethyl sulfoxide and distilled water, respectively. Each solution was then added separately to an acetic acid solution of chitosan (1 mg/ml; Sigma-Aldrich, USA). After complete dissolution and homogenization, sodium tripolyphosphate solution (0.2 mg/ml) was added dropwise. After one hour, the mixture had fully dissolved and nanoparticles had formed. The nanoparticles were separated by centrifugation at 10,000 rpm for one hour. The resulting precipitate was then dissolved in distilled water and stored at −70°C [15]. Nanoparticle morphology was examined using field-emission scanning electron microscopy (FE-SEM), and particle diameter was measured using dynamic light scattering (DLS).
Animals and experimental groups
Forty male Wistar rats weighing 200–250 g were used in this experimental study. The animals were housed under standard conditions, including a temperature of 22–24°C, a regular 12:12-hour light-dark cycle, adequate ventilation, and free access to food and water.
The rats were randomly assigned to eight groups (n = 5 per group):
Control group: Rats did not undergo surgery and received no treatment.
Phosphate-buffered saline (PBS) group: Animals underwent stereotaxic surgery and received PBS as the solvent for Aβ by intracerebroventricular injection.
AD group: Animals received Aβ1–42 (Sigma-Aldrich, USA) at 10 μg per rat (5 μg in each lateral ventricle) by stereotaxic intracerebroventricular injection [16].
AD-Chitosan group: Rats received chitosan (200 mg/kg) after intracerebroventricular Aβ1–42 injection [17].
AD-Linalool group: Rats received linalool (25 mg/kg) after intracerebroventricular Aβ1–42 injection [18].
AD-nano-Linalool group: Rats received nano-linalool (25 mg/kg) after intracerebroventricular Aβ1–42 injection.
AD-Ascorbic acid group: Rats received ascorbic acid (100 mg/kg) after intracerebroventricular Aβ1–42 injection [12].
AD-nano-Ascorbic acid group: Animals received nano-ascorbic acid (100 mg/kg) after intracerebroventricular Aβ1–42 injection.
Chitosan, linalool, nano-linalool, ascorbic acid, and nano-ascorbic acid were administered once daily by gavage, beginning one day after stereotaxic surgery and continuing for 30 consecutive days, between 9:00 and 10:00 a.m. At the end of the treatment period, the animals were anesthetized with carbon dioxide, their heads were separated, and the brain hemispheres were transferred to formalin fixative.
Stereotaxic surgery and induction of the AD model
All rats except those in the Control group underwent stereotaxic surgery. The animals were first anesthetized by intraperitoneal injection of ketamine (80 mg/kg) and xylazine (20 mg/kg) [19]. The head was fixed in the stereotaxic apparatus, the skull was exposed, and the injection coordinates were identified. The coordinates (AP: −0.8 mm, L: ±1.5 mm, V: 3.8 mm) were selected using a rat brain atlas [20]. In the PBS group, 2 μl of PBS was injected into each ventricle using a Hamilton microsyringe. In the other groups, AD was induced by injecting Aβ1–42 (5 μg in 2 μl) into each lateral ventricle. The injection rate was 1 μl/min. To prevent reflux of PBS or Aβ1–42 from the injection site, the needle was left in place for two minutes after each injection before being withdrawn.
Treatment by daily gavage began one day after surgery and Aβ1–42 injection and continued for 30 consecutive days. One day after the treatment period ended, the animals were deeply anesthetized with carbon dioxide and euthanized, and their brains were removed for histological examination.
Histological examination and plaque quantification
The brain hemispheres were fixed in 10% formalin for 72 hours. The tissues were dehydrated through ascending concentrations of ethanol, and xylene was used for clearing and preparation for paraffin embedding. After embedding, sections were obtained from 2.7–3.7 mm posterior to bregma, the region containing the hippocampus. Ten sections, each 5–6 μm thick, were prepared from each animal using a microtome and transferred to slides. Amyloid plaques were stained with 1% thioflavin S (Sigma-Aldrich, USA). Ten sections from each animal were examined for the presence or absence of amyloid plaque deposition, indicated by green staining, in the CA3 region, and the percentage of plaque deposition was calculated for each animal [21].
Statistical analysis
Data were analyzed using SPSS version 26. Results were expressed as mean ± standard error. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was used to determine differences among groups. A p value < 0.05 was considered statistically significant.
Results
Nanoparticle characteristics
Images of linalool- and ascorbic acid-loaded chitosan nanoparticles obtained by field-emission scanning electron microscopy are presented in Figure 1. The nanoparticles had an approximately spherical structure, were clustered together, and had diameters below 0.2 μm. Dynamic light scattering results confirmed these findings, showing a diameter of 159 nm for linalool nanoparticles and 125 nm for ascorbic acid nanoparticles (Figure 2).
Figure 1. FE-SEM images of linalool-loaded chitosan nanoparticles (right) and ascorbic acid-loaded chitosan nanoparticles (left).
Figure 2. Dynamic light scattering (DLS) results for linalool-loaded chitosan nanoparticles (right) and ascorbic acid-loaded chitosan nanoparticles (left).
Amyloid plaque deposition in the CA3 region
Microscopic examination of thioflavin-stained sections showed extensive amyloid plaque deposition in the AD and AD-Chitosan groups, whereas treatment with linalool, nano-linalool, ascorbic acid, and nano-ascorbic acid largely inhibited plaque deposition (Figure 3). Statistical analysis showed that amyloid plaque deposition in the CA3 region was significantly higher in the AD group than in the Control group (p = 0.00001). In contrast, plaque deposition was significantly lower in the AD-Linalool, AD-nano-Linalool, AD-Ascorbic acid, and AD-nano-Ascorbic acid groups than in the AD group (p = 0.0005, p = 0.0002, p = 0.0002, and p = 0.00008, respectively). Plaque deposition was significantly lower in the AD-nano-Linalool group than in the AD-Linalool group (p = 0.023). It was also significantly lower in the AD-nano-Ascorbic acid group than in the AD-Ascorbic acid group (p = 0.009; Figure 4). No significant differences were observed between the Control and PBS groups or between the AD and AD-Chitosan groups.
Figure 3. Photomicrographs of the hippocampal CA3 region stained with thioflavin. The white arrow indicates an amyloid plaque (×100).
Figure 4. Statistical comparison of the percentage of amyloid plaques in the hippocampal CA3 region. Results are presented as mean ± standard error (n = 5). *** p < 0.001 compared with the Control group; ### p < 0.001 compared with the AD group; ^ p < 0.05 compared with the AD-Linalool group; and && p < 0.01 compared with the AD-Ascorbic acid group. Between-group comparisons were performed using one-way ANOVA.
Discussion
This study was designed to investigate the effect of encapsulating linalool and ascorbic acid in chitosan nanoparticles on amyloid plaque deposition in the CA3 region of the hippocampus in AD model rats. AD was induced by bilateral intracerebroventricular injection of Aβ1–42, which resulted in extensive amyloid plaque deposition in the hippocampal CA3 region after 30 days. This part of the findings is consistent with the report by Halder et al. [22]. After 30 days of treatment with linalool, ascorbic acid, nano-linalool, or nano-ascorbic acid, plaque deposition in the CA3 region of AD model animals was examined and compared.
Microscopic examination of the CA3 region showed that linalool and nano-linalool reduced amyloid plaque deposition in AD model rats. Singh et al. [23] recently demonstrated that linalool binds directly to the Aβ peptide, prevents the formation of Aβ fibrils, and can also promote the disaggregation of pre-existing fibrils in animal models of AD. This report is consistent with the present findings. However, the AD-nano-Linalool group showed a significantly greater reduction in amyloid plaque deposition than the AD-Linalool group. Studies have shown that the concentration of linalool in the brain increases substantially 90 minutes after it enters the body but decreases sharply 30 minutes later [24]. This may represent a major challenge to the ability of linalool to inhibit amyloid plaque deposition. Campos et al. [25] showed that encapsulating linalool and carvacrol in chitosan nanoparticles enables the slow and sustained release of these compounds. Therefore, the significantly lower plaque deposition in the AD-nano-Linalool group than in the AD-Linalool group may be due to prevention of a rapid decline in linalool levels in the brain.
The present study also showed that amyloid plaque deposition was significantly lower in AD model rats treated with ascorbic acid or nano-ascorbic acid than in the AD group. Consistent with this finding, one study reported competition between ascorbic acid and Aβ1–42 monomers for binding to Aβ1–42 oligomers. In particular, ascorbic acid can destabilize small oligomers and may even reverse amyloid fibrillation [26]. In the present study, nano-ascorbic acid was more effective than ascorbic acid in reducing and inhibiting amyloid plaque deposition. Research has shown that expression of the sodium-ascorbate transporter, which plays an essential role in transporting this vitamin into the brain, decreases in the brains of AD model mice. Increasing expression of this transporter improves synaptic plasticity and strengthens memory in these animals [27]. This suggests that ascorbic acid entry into the brain may be impaired in AD model animals. Because chitosan nanoparticles may cross the blood-brain barrier through a transcytosis pathway that is distinct from transporter-mediated entry [28], ascorbic acid levels in the brains of animals in the AD-nano-Ascorbic acid group may differ from those in the AD-Ascorbic acid group because the compound enters through different pathways.
It has also been emphasized that the level of ascorbic acid is important for its antioxidant function in the brain. When the hippocampus is exposed to ozone, ascorbic acid reduces lipid peroxidation in a dose-dependent manner. However, its ability to reduce lipid peroxidation decreases at both low and very high doses [29]. Since oxidative stress plays an important role in Aβ production in the brains of patients with AD [30], and chitosan nanoparticles enable sustained drug release [31], chitosan-based nano-ascorbic acid may maintain ascorbic acid levels in the brains of AD model animals within a balanced range through gradual release, thereby providing neurons with an optimal dose of ascorbic acid.
One limitation of the present study was that linalool and ascorbic acid levels were not measured in the different experimental groups.
Conclusion
Encapsulation of linalool and ascorbic acid in chitosan nanoparticles increases the ability of these natural compounds to reduce amyloid plaque deposition in the CA3 region of the hippocampus in AD model rats.
Ethical Considerations
Compliance with Ethical Guidelines
All procedures involving animals were performed in accordance with ethical principles and under the supervision of the Biomedical Research Ethics Committee of the Science and Research Branch of Islamic Azad University, Tehran, Iran (Ethics Code: IR.IAU.SRB.REC.1402.338).
Funding
This research received no financial support.
Conflict of Interest
The authors declared no conflict of interest.
Authors’ Contributions
Mohammad Pakdel performed the experiments and collected the data. Masoumeh Asle-Rousta conceived and designed the experiments, analyzed the data, and wrote and revised the manuscript. Akram Eidi contributed to the design of the study.
References
- Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 2019;179(2):312-39. doi: 10.1016/j.cell.2019.09.001 pmid
- Ma C, Hong F, Yang S. Amyloidosis in alzheimer’s disease: pathogeny, etiology, and related therapeutic directions. Molecules. 2022;27(4):1210. doi: 10.3390/molecules27041210 pmid
- Lee JH, Ahn NH, Choi SB, Kwon Y, Yang SH. Natural products targeting amyloid beta in Alzheimer’s disease. Int J Mol Sci. 2021;22(5):2341. doi: 10.3390/ijms22052341 pmid
- Aprotosoaie AC, Hăncianu M, Costache II, Miron A. Linalool: a review on a key odorant molecule with valuable biological properties. Flavour fragr J. 2014;29(4):193-219. doi: 10.1002/ffj.3197
- Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. doi: 10.3389/fpsyt.2021.583211 pmid
- Park H, Seol GH, Ryu S, Choi IY. Neuroprotective effects of linalool against oxygen-glucose deprivation-induced neuronal injury. Arch Pharm Res. 2016;39(4):555-64. doi: 10.1007/s12272-016-0714-z pmid
- Chang WH, Hsu HT, Lin CC, An LM, Lee CH, Ko HH, et al. Linalool, a fragrance compound in plants, protects dopaminergic neurons and improves motor function and skeletal muscle strength in experimental models of parkinson’s disease. Int J Mol Sci. 2024;25(5):2514. doi: 10.3390/ijms25052514 pmid
- Sabogal-Guáqueta AM, Osorio E, Cardona-Gómez GP. Linalool reverses neuropathological and behavioral impairments in old triple transgenic Alzheimer's mice. Neuropharmacology. 2016;102:111-20. doi: 10.1016/j.neuropharm.2015.11.002 pmid
- Njus D, Kelley PM, Tu YJ, Schlegel HB. Ascorbic acid: The chemistry underlying its antioxidant properties. Free Radic Biol Med. 2020;159:37-43. doi: 10.1016/j.freeradbiomed.2020.07.013 pmid
- Hamid M, Mansoor S, Amber S, Zahid S. A quantitative meta-analysis of vitamin C in the pathophysiology of Alzheimer’s disease. Front Aging Neurosci. 2022;14:970263. doi: 10.3389/fnagi.2022.970263 pmid
- Nualart F, Mack L, García A, Cisternas P, Bongarzone ER, Heitzer M, et al.. Vitamin C transporters, recycling and the bystander effect in the nervous system: SVCT2 versus gluts. Stem Cell Res Ther. 2014;4(5):209. doi: 10.4172/2157-7633.1000209 pmid
- Olajide OJ, Yawson EO, Gbadamosi IT, Arogundade TT, Lambe E, Obasi K, et al. Ascorbic acid ameliorates behavioural deficits and neuropathological alterations in rat model of Alzheimer’s disease. Environ Toxicol Pharmacol. 2017;50:200-11. doi: 10.1016/j.etap.2017.02.010 pmid
- Manek E, Darvas F, Petroianu GA. Use of biodegradable, chitosan-based nanoparticles in the treatment of Alzheimer’s disease. Molecules. 2020;25(20):4866. doi: 10.3390/molecules25204866 pmid
- Sarvaiya J, Agrawal YK. Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery. Int J Biol Macromol. 2015;72:454-65. doi: 10.1016/j.ijbiomac.2014.08.052 pmid
- Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan–TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces. 2005;44(2-3):65-73. doi: 10.1016/j.colsurfb.2005.06.001 pmid
- Karakelle NA, Dinçer S, Sağlam AS. The effect of intracerebroventricular amyloid beta 1–42 application on cognitive functions in aged rats supplemented with taurine and the change of peroxisomal proteins in this process. Brain Res Bull. 2021;172:89-97. doi: 10.1016/j.brainresbull.2021.04.011 pmid
- Bilginaylar K, Aykac A, Sayiner S, Özkayalar H, Şehirli AÖ. Evaluation of the antiapoptotic and anti-inflammatory properties of chitosan in methotrexate-induced oral mucositis in rats. Mol Biol Rep. 2022;49(4):3237-45. doi: 10.1007/s11033-022-07158-x pmid
- Koriem KM, El-Qady SW. Linalool attenuates hypothalamus proteome disturbance facilitated by methamphetamine induced neurotoxicity in rats. Neurotoxicology. 2023;99:70-81. doi: 10.1016/j.neuro.2023.09.007 pmid
- Oh SS, Narver HL. Mouse and rat anesthesia and analgesia. Curr protoc. 2024;4(2):e995. doi: 10.1002/cpz1.995 pmid
- Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 2006, 6th ed. Academic press, New York. Link
- Pakdel M, Asle-Rousta M, Sadegh M, Eidi A. Linalool vs linalool-loaded chitosan nanoparticles in an Aβ-induced rat model of Alzheimer’s disease: A molecular, biochemical, histological, and behavioral study. Iran J Basic Med Sci. 2025;28(11):1495-1504. doi: 10.22038/ijbms.2025.88638.19143 pmid
- Halder T, Saha B, Dhas N, Acharya S, Acharya N. Development and evaluation of multi‐functionalized sialic acid conjugated asiatic acid nanoconstruct to mitigate cognitive deficits in Alzheimer's disease. Drug Dev Res. 2024;85(1):e22146. doi: 10.1002/ddr.22146 pmid
- Singh R, Kaur N, Dhingra N, Kaur T. Linalool acts as a chemical chaperone by inhibiting amyloid-β aggregation. Neurochem Int. 2024;177:105762. doi: 10.1016/j.neuint.2024.105762 pmid
- Satou T, Hayakawa M, Kasuya H, Masuo Y, Koike K. Mouse brain concentrations of α‐pinene, limonene, linalool, and 1, 8‐cineole following inhalation. Flavour Fragr J. 2017;32(1):36-9. doi: 10.1002/ffj.3342
- Campos EV, Proença PL, Oliveira JL, Pereira AE, de Morais Ribeiro LN, Fernandes FO, et al. Carvacrol and linalool co-loaded in β-cyclodextrin-grafted chitosan nanoparticles as sustainable biopesticide aiming pest control. Sci Rep. 2018;8(1):7623. doi: 10.1038/s41598-018-26043-x pmid
- Sampaio I, Quatroni FD, Lins PM, Nascimento AS, Zucolotto V. Modulation of beta-amyloid aggregation using ascorbic acid. Biochimie. 2022;200:36-43. doi: 10.1016/j.biochi.2022.05.006 pmid
- Portugal CC, Santos EC, Pacheco AM, Costa-Pinto S, Almeida TO, Tedim-Moreira J, et al. Increasing the vitamin C transporter SVCT2 in microglia improves synaptic plasticity and restrains memory impairments in Alzheimer’s disease models. bioRxiv. 2024 doi: 10.1101/2024.02.29.582679
- Caprifico AE, Foot PJ, Polycarpou E, Calabrese G. Overcoming the blood-brain barrier: Functionalised chitosan nanocarriers. Pharmaceutics. 2020;12(11):1013. doi: 10.3390/pharmaceutics12111013 pmid
- Figueroa-Méndez R, Rivas-Arancibia S. Vitamin C in health and disease: its role in the metabolism of cells and redox state in the brain. Front Physiol. 2015;6:397. doi: 10.3389/fphys.2015.00397 pmid
- Cai Z, Zhao B, Ratka A. Oxidative stress and β-amyloid protein in Alzheimer’s disease. Neuromolecular Med. 2011;13(4):223-50. doi: 10.1007/s12017-011-8155-9 pmid
- Patra JK, Das G, Fraceto LF, Campos EV, Rodriguez-Torres MD, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J nanobiotechnology. 2018;16(1):71. doi: 10.1186/s12951-018-0392-8 pmid
